Dr. Saied Safabakhsh, M.D. Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 736 Route 4, Suite 103, Sinajana, GU 96910 Phone: 671-649-7232 Fax: 671-649-7233 |
Dr. Robert Caing Nerves, MD, FACP, FPCP Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 736 Route 4, Suite 103, Sinajana, GU 96910 Phone: 671-649-7232 Fax: 671-649-7233 |
News Archive
Development of a fundamentally new "candidate," or potential, vaccine for visceral leishmaniasis (LEASH-ma-NIGH-a-sis), a parasitic disease that kills about 60,000 people annually, is reported in the current issue of ACS Chemical Biology. Spread by the bite of infected female sand flies, visceral leishmaniasis infects about 500,000 people annually, with the majority of cases occurring in India, Bangladesh, Nepal, Sudan and Brazil.
Atypical development can be detected as early as 12 months of age among the siblings of children with autism spectrum disorder, a study published by researchers with the UC Davis MIND Institute and UCLA has found.
DUSA Pharmaceuticals, Inc.(R)( )(Nasdaq: DUSA), a specialty pharmaceutical company focused on dermatology, announced today that it has been named to Deloitte's Technology Fast 500 list. For the second consecutive year, Deloitte recognized DUSA as one of the Top 500 fastest growing technology, media, telecommunications and life sciences companies in North America in terms of percentage revenue growth over a five year period.
Veracyte, Inc., a molecular diagnostics company pioneering the field of molecular cytology, today announced that two Blue Cross Blue Shield–affiliated organizations, Highmark Inc. and Horizon Blue Cross Blue Shield of New Jersey, have issued positive coverage policies for the company's Afirma Gene Expression Classifier (GEC).
› Verified 4 days ago